Kite claims a first for CAR-T Tecartus in adult leukaemiaThe FDA has approved Kite Pharma’s Tecartus as a treatment for adults with relapsed or refractory B-cell precursor Share XKite claims a first for CAR-T Tecartus in adult leukaemiahttps://pharmaphorum.com/news/kite-claims-a-first-for-car-t-tecartus-in-adult-leukaemia/
Novartis’ bid to extend Kymriah into earlier use hits a roadblockNovartis’ CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few Share XNovartis’ bid to extend Kymriah into earlier use hits a roadblockhttps://pharmaphorum.com/news/novartis-bid-to-extend-kymriah-into-earlier-use-hits-a-roadblock/
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus dataNovartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but Share XASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus datahttps://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/
Casting aside CRISPR scissors and making a point with base editorsDr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at Share XCasting aside CRISPR scissors and making a point with base editorshttps://pharmaphorum.com/r-d/views-analysis-r-d/immune-cell-therapies-crispr-cas9-gene-editing/
FDA hastens development of Novartis’ Kymriah in follicular lymphomaNovartis will receive extra help from the FDA during the development of its CAR-T cancer cell therapy Kymriah Share XFDA hastens development of Novartis’ Kymriah in follicular lymphomahttps://pharmaphorum.com/news/fda-hastens-development-of-novartis-kymriah-in-follicular-lymphoma/
Real-world data backs Kymriah’s safety profile, says NovartisWith more competition looming for its CAR-T therapy Kymriah, Novartis has pointed to new data that show the Share XReal-world data backs Kymriah’s safety profile, says Novartishttps://pharmaphorum.com/news/real-world-data-backs-kymriahs-safety-profile-says-novartis/
Novartis’ Kymriah okayed for funding in Scotland for lymphomaNovartis’ Kymriah has become the first CAR-T available to NHS patients across the UK after Scotland’s medicines cost-effectiveness Share XNovartis’ Kymriah okayed for funding in Scotland for lymphomahttps://pharmaphorum.com/news/novartis-kymriah-okayed-for-funding-in-scotland-for-lymphoma/
Will cell and gene therapies disrupt reimbursement?Cell and gene therapies could prove disruptive in terms of the life-changing benefits they could bring to people Share XWill cell and gene therapies disrupt reimbursement?https://deep-dive.pharmaphorum.com/magazine/disruptive-technologies/will-cell-and-gene-therapies-disrupt-drug-reimbursement/
Scotland says no to Yescarta, but backs KymriahScotland’s cost-effectiveness watchdog has decided against making Gilead’s CAR-T therapy Yescarta routinely available to patients with two types Share XScotland says no to Yescarta, but backs Kymriahhttps://pharmaphorum.com/news/scotland-says-no-to-yescarta-but-backs-kymriah/
